<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02039219</url>
  </required_header>
  <id_info>
    <org_study_id>TREAT 002</org_study_id>
    <secondary_id>1U01AA021840-01</secondary_id>
    <secondary_id>U01AA021883</secondary_id>
    <secondary_id>U01AA021891</secondary_id>
    <secondary_id>U01AA021788</secondary_id>
    <nct_id>NCT02039219</nct_id>
  </id_info>
  <brief_title>Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH)</brief_title>
  <acronym>TREAT</acronym>
  <official_title>A Double-Blind, Placebo-Controlled Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Naga P. Chalasani</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Intercept Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to test the effectiveness of Obeticholic Acid when used in
      patients with moderately severe alcoholic hepatitis. The researchers suspect that individuals
      with alcoholic hepatitis have certain abnormalities in how their body handles bile acids (a
      product made by the liver on a daily basis) produced by the liver. Obeticholic acid has been
      shown to affect bile acid abnormalities and thus it is possible that obeticholic acid may
      improve liver condition in individuals with alcoholic hepatitis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in MELD score at 6 weeks</measure>
    <time_frame>baseline to 6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of serious adverse events (SAEs) during the treatment phase</measure>
    <time_frame>baseline to 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Any SAEs during the follow-up phase</measure>
    <time_frame>Days 42 to 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAEs attributable to the study medicine during the treatment and follow-up phases</measure>
    <time_frame>Days 42 to 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs) and discontinuation rates during the treatment and follow-up phases</measure>
    <time_frame>days 42 to 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in MELD score at 90 and 180 days</measure>
    <time_frame>day 90 and 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Child-Pugh score at 6 weeks and at 90 and 180 days</measure>
    <time_frame>Day 90 and 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate at Week 6 and at 90 and 180 days</measure>
    <time_frame>Week 6 and Days 90 and 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of hospitalization</measure>
    <time_frame>baseline to day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in intestinal inflammation</measure>
    <time_frame>baseline to day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum oxidative stress.</measure>
    <time_frame>baseline to day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stays</measure>
    <time_frame>Baseline to 180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in bacterial translocation</measure>
    <time_frame>baseline to 180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cytokines</measure>
    <time_frame>baseline to 180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in activation of innate immunity</measure>
    <time_frame>baseline to 180 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg Obeticholic Acid (OCA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 6 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10 mg Obeticholic Acid (OCA)</intervention_name>
    <description>10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 6 weeks.</description>
    <arm_group_label>10 mg Obeticholic Acid (OCA)</arm_group_label>
    <other_name>INT-747</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals â‰¥ 21 years with a diagnosis of acute AH. The diagnosis of acute alcoholic
             hepatitis will be based on clinical features and testing including hepatomegaly,
             jaundice, fever, leukocytosis, compatible liver biochemistries in the context of heavy
             alcohol consumption. A liver biopsy is not mandatory, but will be required to confirm
             the diagnosis if a firm diagnosis of AH cannot be made on clinical and laboratory
             criteria

          -  Moderate severity defined as MELD score &gt; 11 and &lt; 20

          -  Heavy alcohol consumption (defined as &gt; 40 grams per day on average in women and &gt; 60
             grams per day on average in men for a minimum of 6 months and within the 6 weeks prior
             to study enrollment)

          -  Written informed consent

          -  Negative urine pregnancy test where appropriate

          -  Women of child bearing potential should be willing to practice contraception
             throughout the treatment period

        Exclusion Criteria:

          -  Significant active infection (e.g., sepsis, or spontaneous bacterial peritonitis;
             SBP). Subjects can be reconsidered after the infection is under control.

          -  Serum creatinine &gt; 2.5 mg/dL

          -  Must not be receiving systemic steroids &gt; 1 week at the time of Screening or any
             experimental medicines for AH

          -  Presence of any other disease or condition that is interfering with the absorption,
             distribution, metabolism, or excretion of drugs including bile salt metabolism in the
             intestine. Patients who have undergone gastric bypass procedures will be excluded
             (gastric lap band is acceptable).

          -  Participation in another investigational drug, biologic, or medical device trial
             within 30 days prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naga Chalasani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Lehman, RN</last_name>
    <phone>317-278-1872</phone>
    <email>jgeck@iu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Megan Comerford, BS, MPH</last_name>
    <phone>3172789226</phone>
    <email>mcomerfo@iu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Lehman, RN</last_name>
      <phone>317-278-1872</phone>
      <email>jgeck@iu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Megan Comerford, BS, MPH</last_name>
      <phone>(317) 278-9226</phone>
      <email>mcomerfo@iu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Naga Chalasani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suthat Liangpunsakul, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Crabb, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Wilder, RN, BSN</last_name>
      <phone>507-284-2698</phone>
      <email>wilder.sarah@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Vijay Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Einstein Healthcare Network</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taja Towne, MSW</last_name>
      <phone>215-456-8721</phone>
      <email>TowneTaj@einstein.edu</email>
    </contact>
    <investigator>
      <last_name>Victor Navarro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manisha Verma, MD, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simona Rossi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virgina Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Walker, RN, MSN</last_name>
      <phone>804-628-4395</phone>
      <email>walkersa@vcu.edu</email>
    </contact>
    <investigator>
      <last_name>Arun J Sanyal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://alcoholichepatitis.org/</url>
    <description>TREAT Consortium Website</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2014</study_first_submitted>
  <study_first_submitted_qc>January 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2014</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University School of Medicine</investigator_affiliation>
    <investigator_full_name>Naga P. Chalasani</investigator_full_name>
    <investigator_title>Naga Chalasani, MD, FACG</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chenodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

